Expert Backs Medtronic's IP Pricing In $1.36B Tax Court Trial
Medtronic's patent licensing arrangement with a competitor is a valid comparison when determining intercompany royalty rates, an intellectual property and economics expert testified Wednesday during the corporation's $1.36 billion transfer pricing...To view the full article, register now.
Already a subscriber? Click here to view full article